Información del artículo
Resumen
Un número creciente de pacientes críticamente enfermos son atendidos por sepsis secundaria a infecciones bacterianas o micóticas. En este grupo de pacientes la sepsis per se es un factor de riesgo para el desarrollo de falla renal, la cual implica un mayor riesgo de mortalidad. Un panel de expertos en las áreas de infectología, cuidado crítico y nefrología prepararon un consenso basado en la información actual (“evidencia”) sobre el uso de antimicrobianos (antibióticos y antifúngicos) en pacientes críticamente enfermos con falla renal o en riesgo de padecerla. Se identificó la literatura científica relevante mediante un proceso de búsqueda sistemática y se generaron recomendaciones por medio del método presencial Delphi. Se propone que las recomendaciones de este consenso sean utilizadas por los trabajadores de la salud que manejen este grupo de pacientes, con el fin de identificar aquellos en mayor riesgo de progresión a falla renal y establecer las estrategias terapéuticas que tengan el mayor beneficio con la menor probabildad de efectos secundarios serios sobre la función renal. Se adicionó una estrategia para la implmentación de estas recomendaciones.
Palabras clave:
Agentes antibacterianos
agentes antifúngicos
insuficiencia renal
lesión renal aguda
consenso
toxicidad de drogas
Abstract
A growing number of critically ill patients are being taken care with sepsis secondary to bacterial or mycotic infections. In this group of patients, sepsis per se is a risk factor for the development of renal failure, which has been related to an increased risk of hospital mortality. An expert panel in infectious diseases, critical care and renal diseases prepared an evidence based consensus over the use of antimicrobials (antibacterial and antifungal agents) in critically ill patients with renal failure or at risk of suffering it. A sytematic review of the scientific literature was performed and recommendations were established by means of a consensus using the Delphi method. Recommendations proposed by this consensus are intended to be use by healthcare workers who are in charge of this kind of patients with the aim to identify the group of patients with higher risk of developing renal failure and to establish the therapeutic measures theat have the best outcome and lower frequency of severe side effects in renal function. An implementation strategy was added with the recommendations.
Key words:
Antibacterial agents
antifungal agents
acute renal failure
acute renal injury
consensus
drug toxicity
El Texto completo está disponible en PDF
Referencias
[1.]
F. Molina, N. Fonseca, C. Jaramillo, S. Mejía, J. Arango, F. Benitez, et al.
Epidemiología de las infecciones nosocomiales asociadas a dispositivos en 35 unidades de cuidados intensivos de Colombia (2007–2008).
Acta Col Cuid Intens, 9 (2009), pp. 15
[2.]
V.D. Rosenthal, D.G. Maki, S. Jamulitrat, E.A. Medeiros, S.K. Todi, D.Y. Gómez, et al.
International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003–2008, issued June 2009.
Am J Infect Control, 38 (2010), pp. 95-104e0
[3.]
N. Nin, R. Lombardi, F. Frutos-Vivar, A. Esteban, J.A. Lorente, N.D. Ferguson, et al.
Early and small changes in serum creatinine concentrations are associated with mortality in mechanically ventilated patients.
Shock, 34 (2010), pp. 109-116
[4.]
N.J. Fonseca, D.P. Castro, A.M. Guerra, F.M. Saldarriaga, J.D. Hernández.
Renal injury study in critical ill patients in accordance with the new definition given by the Acute Kidney Injury Network.
J Crit Care, 26 (2011), pp. 206-212
[5.]
SIGN. Scottish Intercollegiate Guidelines Network. Critical Appraisal: Notes and Checklists, 2010. Fecha de consulta: 1 diciembre de 2010. Disponible en: http://www.sign.ac.uk/methodology/checklists.html.
[6.]
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman.
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
Int J Surg, 8 (2010), pp. 336-341
[7.]
E. Astigarraga.
El método Delphi.
Universidad de Deusto, (2003),
[8.]
J. de Meyrick.
The Delphi method and health research.
Health Education, 103 (2003), pp. 7-16
[9.]
J. Elliot, S. Heesterbeek, C. Lukensmeyer, N. Slocum.
Participatory Methods Toolkit. A practitioner's manual.
King Baudouin Foundation y Flemish Institute for Science and Technology Assesment, (2005),
[10.]
H. Linstone, M. Turoff.
Delphi method: Techniques and applications.
Addison-Wesley Educational Publishers Inc, (1975),
[11.]
R. Sánchez, L. Jaramillo.
Methodology of qualification and summary of the opinions in formal consensus.
Rev Colomb Psiquiatr, 38 (2009), pp. 777-786
[12.]
H.W. Smith.
The kidney: Structure and function in health and disease.
Oxford University Press, (1951),
[13.]
R. Bellomo.
Defining, quantifying, and classifying acute renal failure.
Crit Care Clin, 21 (2005), pp. 223-237
[14.]
S. Uchino, J.A. Kellum, R. Bellomo, G.S. Doig, H. Morimatsu, S. Morgera, et al.
Acute renal failure in critically ill patients: A multinational, multicenter study.
JAMA, 294 (2005), pp. 813-818
[15.]
J.A. Kellum.
Acute kidney injury.
Crit Care Med, 36 (2008), pp. S141-S145
[16.]
R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, P. Palevsky.
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
Crit Care, 8 (2004), pp. R204-R212
[17.]
R.L. Mehta, J.A. Kellum, S.V. Shah, B.A. Molitoris, C. Ronco, D.G. Warnock, et al.
Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury.
Crit Care, 11 (2007), pp. R31
[18.]
S.M. Bagshaw, C. George, R. Bellomo.
A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients.
Nephrol Dial Transplant, 23 (2008), pp. 1569-1574
[19.]
E.A. Hoste, J.A. Kellum.
Incidence, classification, and outcomes of acute kidney injury.
Contrib Nephrol, 156 (2007), pp. 32-38
[20.]
M.E. Plaut, J.J. Schentag, W.J. Jusko.
Aminoglycoside nephrotoxicity: Comparative assessment in critically ill patients.
J Med, 10 (1979), pp. 257-266
[21.]
M.A. French, F.B. Cerra, M.E. Plaut, J.J. Schentag.
Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.
Antimicrob Agents Chemother, 19 (1981), pp. 147-152
[22.]
J.J. Schentag, M.E. Plaut, F.B. Cerra.
Comparative nephrotoxicity of gentamicin and tobramycin: Pharmacokinetic and clinical studies in 201 patients.
Antimicrob Agents Chemother, 19 (1981), pp. 859-866
[23.]
J.J. Schentag, F.B. Cerra, M.E. Plaut.
Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.
Antimicrob Agents Chemother, 21 (1982), pp. 721-726
[24.]
J.J. Schentag.
Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients.
J Clin Pharmacol, 23 (1983), pp. 473-483
[25.]
P.E. Marik, J. Lipman, S. Kobilski, J. Scribante.
A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.
J Antimicrob Chemother, 28 (1991), pp. 753-764
[26.]
G. Beaucaire, O. Leroy, C. Beuscart, P. Karp, C. Chidiac, M. Caillaux.
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
J Antimicrob Chemother, 27 (1991), pp. 91-103
[27.]
J.S. Bertino Jr., L.A. Booker, P.A. Franck, P.L. Jenkins, K.R. Franck, A.N. Nafziger.
Incidence of and significant risk factors for aminoglycosideassociated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.
J Infect Dis, 167 (1993), pp. 173-179
[28.]
K.M. Olsen, M.I. Rudis, J.A. Rebuck, J. Hara, D. Gelmont, R. Mehdian, et al.
Effect of once-daily dosing Vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity.
Crit Care Med, 32 (2004), pp. 1678-1682
[29.]
J.F. Oliveira, C.A. Silva, C.D. Barbieri, G.M. Oliveira, D.M. Zanetta, E.A. Burdmann.
Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units.
Antimicrob Agents Chemother, 53 (2009), pp. 2887-2891
[30.]
B.F. Farber, R.C. Moellering Jr..
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.
Antimicrob Agents Chemother, 23 (1983), pp. 138-141
[31.]
T. Iwamoto, Y. Kagawa, M. Kojima.
Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin.
Biol Pharm Bull, 26 (2003), pp. 876-879
[32.]
J.H. Martin, R. Norris, M. Barras, J. Roberts, R. Morris, M. Doogue, et al.
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Clin Biochem Rev, 31 (2010), pp. 21-24
[33.]
M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, M. Billeter, et al.
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Am J Health Syst Pharm, 66 (2009), pp. 82-98
[34.]
O. Rodríguez Colomo, F. Álvarez Lerma, B. Álvarez Sanchez, R. Oltra Chorda, F. Barcenilla Gaite, E. Cereijo Martin-Grande, et al.
Use of antibiotics for the treatment of multiresistant Gram positive cocci infections in critical patients.
Med Intensiva, 32 (2008), pp. 263-271
[35.]
A.L. Somerville, D.H. Wright, J.C. Rotschafer.
Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.
Pharmacotherapy, 19 (1999), pp. 702-707
[36.]
P.F. Smith, G.D. Morse.
Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease.
Ann Pharmacother, 33 (1999), pp. 1329-1335
[37.]
T.P. Lodise, B. Lomaestro, J. Graves, G.L. Drusano.
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
Antimicrob Agents Chemother, 52 (2008), pp. 1330-1336
[38.]
P. Malacarne, S. Bergamasco, C. Donadio.
Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients.
Chemotherapy, 52 (2006), pp. 178-184
[39.]
D. Hutschala, C. Kinstner, K. Skhirdladze, F. Thalhammer, M. Muller, E. Tschernko.
Influence of vancomycin on renal function in critically ill patients after cardiac surgery: Continuous versus intermittent infusion.
Anesthesiology, 111 (2009), pp. 356-365
[40.]
M.E. DelDot, J. Lipman, S.E. Tett.
Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
Br J Clin Pharmacol, 58 (2004), pp. 259-268
[41.]
E. Fiaccadori, U. Maggiore, A. Arisi, A. Cabassi, C. Beghi, R. Campodonico, et al.
Outbreak of acute renal failure due to cefodizimevancomycin association in a heart surgery unit.
Intensive Care Med, 27 (2001), pp. 1819-1822
[42.]
P. Charbonneau, I. Harding, J.J. Garaud, J. Aubertin, F. Brunet, Y. Domart.
Teicoplanin: A well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients.
Intensive Care Med, 20 (1994), pp. S35-S42
[43.]
S. Choufane, E. Lobjoie, F. Tinturier.
Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics.
Ann Fr Anesth Reanim, 15 (1996), pp. 1168-1172
[44.]
R.L. Reed 2nd, A.H. Wu, P. Miller-Crotchett, J. Crotchett, R.P. Fischer.
Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients.
J Trauma, 29 (1989), pp. 1462-1470
[45.]
F.T. Boereboom, F.F. Ververs, P.J. Blankestijn, T.J. Savelkoul, A. van Dijk.
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
Intensive Care Med, 25 (1999), pp. 1100-1104
[46.]
F. Pea, L. Brollo, P. Viale, F. Pavan, M. Furlanut.
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose.
J Antimicrob Chemother, 51 (2003), pp. 971-975
[47.]
M.E. Falagas, S.K. Kasiakou.
Toxicity of polymyxins: A systematic review of the evidence from old and recent studies.
Crit Care, 10 (2006), pp. R27
[48.]
M. Paul, J. Bishara, A. Levcovich, M. Chowers, E. Goldberg, P. Singer, et al.
Effectiveness and safety of colistin: Prospective comparative cohort study.
J Antimicrob Chemother, 65 (2010), pp. 1019-1027
[49.]
M.E. Falagas, K.N. Fragoulis, S.K. Kasiakou, G.J. Sermaidis, A. Michalopoulos.
Nephrotoxicity of intravenous colistin: A prospective evaluation.
Int J Antimicrob Agents, 26 (2005), pp. 504-507
[50.]
C.Y. Cheng, W.H. Sheng, J.T. Wang, Y.C. Chen, S.C. Chang.
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
Int J Antimicrob Agents, 35 (2010), pp. 297-300
[51.]
M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, D.E. Karageorgopoulos, et al.
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients.
Int J Antimicrob Agents, 35 (2010), pp. 194-199
[52.]
C. Santamaria, A. Mykietiuk, E. Temporiti, M.E. Stryjewski, F. Herrera, P. Bonvehi.
Nephrotoxicity associated with the use of intravenous colistin.
Scand J Infect Dis, 41 (2009), pp. 767-769
[53.]
S. Ramasubban, A. Majumdar, P.S. Das.
Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock.
Indian J Crit Care Med, 12 (2008), pp. 153-157
[54.]
C.A. Mendes, J.A. Cordeiro, E.A. Burdmann.
Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
Ann Pharmacother, 43 (2009), pp. 1948-1955
[55.]
F. Alvarez, C.L. Gil.
Clinical experience with meropenem in the treatment of severe infections in critically ill patients.
Rev Esp Quimioter, 11 (1998), pp. 229-237
[56.]
J. Hoffman, J. Trimble, G.M. Brophy.
Safety of imipenem/cilastatin in neurocritical care patients.
Neurocrit Care, 10 (2009), pp. 403-407
[57.]
O. Burkhardt, C. Hafer, V. Kaever, H. Haller, T. Welte, J.T. Kielstein.
Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.
Clin Microbiol Infect, 15 (2009), pp. 1
[58.]
G.G. Zhanel, R. Wiebe, L. Dilay, K. Thomson, E. Rubinstein, D.J. Hoban, et al.
Comparative review of the carbapenems.
Drugs, 67 (2007), pp. 1027-1052
[59.]
R. Redman, T.M. File Jr..
Safety of intravenous infusion of doripenem.
Clin Infect Dis, 49 (2009), pp. S28-S35
[60.]
T.M. Chapuis, E. Giannoni, P.A. Majcherczyk, R. Chiolero, M.D. Schaller, M.M. Berger, et al.
Prospective monitoring of cefepime in intensive care unit adult patients.
Crit Care, 14 (2010), pp. R51
[61.]
D. Chatellier, M. Jourdain, J. Mangalaboyi, F. Ader, C. Chopin, P. Derambure, et al.
Cefepime-induced neurotoxicity: An underestimated complication of antibiotherapy in patients with acute renal failure.
Intensive Care Med, 28 (2002), pp. 214-217
[62.]
A. Torres, R. de Celis, E. Rabinad, F. Marco, M. Almela, R. Deulofeu, et al.
Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime.
Chemotherapy, 35 (1989), pp. 15-24
[63.]
E. Cordero, E. Bouza, I. Ruiz, J. Pachon.
Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: An open, randomized trial.
J Antimicrob Chemother, 48 (2001), pp. 527-534
[64.]
K.H. Polderman, A.R. Girbes.
Piperacillin-induced magnesium and potassium loss in intensive care unit patients.
Intensive Care Med, 28 (2002), pp. 520-522
[65.]
G. Capellier, C. Cornette, A. Boillot, C. Guinchard, T. Jacques, G. Blasco, et al.
Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration.
Crit Care Med, 26 (1998), pp. 88-91
[66.]
A. Arzuaga, J. Maynar, A.R. Gascon, A. Isla, E. Corral, F. Fonseca, et al.
Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
J Clin Pharmacol, 45 (2005), pp. 168-176
[67.]
E. Boselli, D. Breilh, T. Rimmele, C. Guillaume, F. Xuereb, M.C. Saux, et al.
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Crit Care Med, 36 (2008), pp. 1500-1506
[68.]
S.M. Bagshaw, S. Lapinsky, S. Dial, Y. Arabi, P. Dodek, G. Wood, et al.
Acute kidney injury in septic shock: Clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy.
Intensive Care Med, 35 (2009), pp. 871-881
[69.]
M.D. Churchwell, D.A. Pasko, B.A. Mueller.
Daptomycin clearance during modeled continuous renal replacement therapy.
Blood Purif, 24 (2006), pp. 548-554
[70.]
P.E. Pertel, B.I. Eisenstein, A.S. Link, B. Donfrid, E.J. Biermann, P. Bernardo, et al.
The efficacy and safety of daptomycin Vs. vancomycin for the treatment of cellulitis and erysipelas.
Int J Clin Pract, 63 (2009), pp. 368-375
[71.]
T. Lalani, H.W. Boucher, S.E. Cosgrove, V.G. Fowler, Z.A. Kanafani, G.A. Vigliani, et al.
Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
J Antimicrob Chemother, 61 (2008), pp. 177-182
[72.]
V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, M.E. Rupp, et al.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
N Engl J Med, 355 (2006), pp. 653-665
[73.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[74.]
S.M. Bhavnani, A. Prakhya, J.P. Hammel, P.G. Ambrose.
Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
Clin Infect Dis, 49 (2009), pp. 691-698
[75.]
L. Beibei, C. Yun, C. Mengli, B. Nan, Y. Xuhong, W. Rui.
Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: Meta-analysis of randomized controlled trials.
Int J Antimicrob Agents, 35 (2010), pp. 3-12
[76.]
S.A. Myre, J. McCann, M.R. First, R.J. Cluxton Jr..
Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers.
Ther Drug Monit, 9 (1987), pp. 161-165
[77.]
A.D. Luber, L. Maa, M. Lam, B.J. Guglielmo.
Risk factors for amphotericin B-induced nephrotoxicity.
J Antimicrob Chemother, 43 (1999), pp. 267-271
[78.]
S. Harbarth, S.L. Pestotnik, J.F. Lloyd, J.P. Burke, M.H. Samore.
The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.
Am J Med, 111 (2001), pp. 528-534
[79.]
P.O. Gubbins, S.R. Penzak, S. Polston, S.A. McConnell, E. Anaissie.
Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.
Pharmacotherapy, 22 (2002), pp. 961-971
[80.]
J.R. Wingard, P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, et al.
Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Clin Infect Dis, 29 (1999), pp. 1402-1407
[81.]
D.W. Bates, L. Su, D.T. Yu, G.M. Chertow, D.L. Seger, D.R. Gomes, et al.
Correlates of acute renal failure in patients receiving parenteral amphotericin B.
Kidney Int, 60 (2001), pp. 1452-1459
[82.]
I.A. Malik, I. Moid, Z. Aziz, S. Khan, M. Suleman.
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
Am J Med, 105 (1998), pp. 478-483
[83.]
A.N. Bower, H.M. Tang, B.J. Guglielmo.
Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B.
Am J Health Syst Pharm, 61 (2004), pp. 915-920
[84.]
J.M. Constantin, L. Roszyk, R. Guerin, F. Bannier, C. Chartier, S. Perbet, et al.
Tolerance of caspofungin in intensive care unit: A prospective study.
Ann Fr Anesth Reanim, 27 (2008), pp. 819-824
[85.]
O. Lortholary, A. Charlemagne, F. Bastides, P. Chevalier, A. Datry, M.F. Gonzalves, et al.
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998–1999.
J Antimicrob Chemother, 54 (2004), pp. 456-464
[86.]
M.E. Eichhorn, H. Wolf, H. Kuchenhoff, M. Joka, K.W. Jauch, W.H. Hartl.
Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients.
Eur J Clin Microbiol Infect Dis, 26 (2007), pp. 395-402
[87.]
J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. van der Horst, J.E. Edwards, et al.
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
N Engl J Med, 331 (1994), pp. 1325-1330
[88.]
O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, A.J. Ullmann, T.J. Walsh, et al.
Posaconazole Vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med, 356 (2007), pp. 348-359
[89.]
B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, J.H. Rex, et al.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomized non-inferiority trial.
Lancet, 366 (2005), pp. 1435-1442
[90.]
F. Álvarez-Lerma, A. Allepuz-Palau, M.P. García, M. Ángeles-León, A. Navarro, H. Sanchez-Ruiz, et al.
Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.
J Chemother, 20 (2008), pp. 93-100
[91.]
M.J. DiNubile, R.J. Lupinacci, K.M. Strohmaier, C.A. Sable, N.A. Kartsonis.
Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial.
J Crit Care, 22 (2007), pp. 237-244
[92.]
J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, J. Smietana, et al.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med, 347 (2002), pp. 2020-2029
[93.]
B.F. Dupont, O. Lortholary, L. Ostrosky-Zeichner, F. Stucker, V. Yeldandi.
Treatment of candidemia and invasive candidiasis in the intensive care unit: Post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
Crit Care, 13 (2009), pp. R159
[94.]
E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, et al.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomized double-blind trial.
Lancet, 369 (2007), pp. 1519-1527
[95.]
J.E. Céspedes, F. Molina, H. Cáceres, A. Spath, M. Vivas, C.M. Tamayo, et al.
Costo-efectividad de linezolid versus vancomicina en el tratamiento de la neumonía asociada a ventilación mecánica (NAV) por Staphylococcus aureus resistente a la meticilina (SARM) en Colombia.
Acta Col Cuid Intens, 7 (2007), pp. 10-25
[96.]
F. Molina, C. Izquierdo, H. Cáceres, J.A. Cortés, R. Soto.
Análisis de costo efectividad de linezolid Vs. vancomicina en pacientes con sospecha de Staphylococcus aureus resistente a la meticilina en neumonía asociada a respiración mecánica asistida en Colombia.
Infectio, 14 (2010), pp. 1
[97.]
F. Molina, J.A. Cortés, H. Cáceres, R. Soto, E. Lemos.
Análisis de costo efectividad de los tratamientos antimicóticos disponibles en Colombia para la candidiasis invasiva.
Infectio, 14 (2010), pp. 1
[98.]
P. Dennen, I.S. Douglas, R. Anderson.
Acute kidney injury in the intensive care unit: An update and primer for the intensivist.
Crit Care Med, 38 (2010), pp. 261-275
Copyright © 2011. Asociación Colombiana de Infectología (ACIN)
